Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (11): 990-995.doi: 10.35541/cjd.20210692

• Original Articles • Previous Articles     Next Articles

Effects of resveratrol on the activity of infantile hemangioma-derived endothelial cells

Yang Kaiying1, Qiu Tong1, Gong Xue1, Lan Yuru1, Zhou Jiangyuan1, Chen Siyuan2, Ji Yi1   

  1. 1Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; 2Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
  • Received:2021-09-22 Revised:2022-04-18 Online:2022-11-15 Published:2022-11-03
  • Contact: Ji Yi E-mail:jijiyuanyuan@163.com
  • Supported by:
    National Natural Science Foundation of China (81401606, 81400862); Key Project in the Science & Technology Program of Sichuan Province (2019YFS0322); Science Foundation for Excellent Youth Scholars of Sichuan University (2015SU04A15); The 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital of Sichuan University (2019HXFH056, 2020HXFH048, ZYJC21060)

Abstract: 【Abstract】 Objective To investigate the effect of the glucose transporter 1 (Glut-1) inhibitor resveratrol on the activity of infantile hemangioma (IH)-derived endothelial cells (HemEC). Methods IH tissues were collected from 4 cases of proliferating IH and 4 cases of involuting IH, and immunohistochemical study was performed to determine the Glut-1 expression. Primary HemEC were extracted from 4 proliferating IH tissues, real-time fluorescence-based quantitative PCR(qPCR) and Western blot analysis were performed to determine the mRNA and protein expression of Glut-1 in HemEC and human umbilical vein endothelial cells (HUVEC), respectively. HemEC were cultured in vitro and treated with 0 (control group), 50, 100, 200, 400 and 800 μmol/L resveratrol for 24 hours, respectively. Cell counting kit-8 (CCK8) assay was performed to evaluate the proliferative ability of HemEC in the above groups, and the 50% inhibitory concentration (IC50) was calculated. The migratory ability and apoptosis level of HemEC were assessed by Transwell assay and flow cytometry, respectively. Intergroup comparisons were performed using t test or analysis of variance, and multiple comparisons were performed using least significant difference-t test. Results Immunohistochemical study showed that Glut-1 was expressed in vascular endothelial cells derived from both proliferating and involuting IH tissues, and the Glut-1 expression was abundant in the proliferating IH but markedly decreased in the involuting IH tissues. The mRNA and protein expression levels of Glut-1 were significantly higher in HemEC (1.793 ± 0.041, 1.959 ± 0.144, respectively) than in HUVEC (0.820 ± 0.073, 0.648 ± 0.046, t = 16.35, 12.28, respectively, both P < 0.001). After the treatment with Glut-1 inhibitor resveratrol at different concentrations, the proliferative ability of HemEC significantly differed among the control group, 50-, 100-, 200-, 400- and 800-μmol/L resveratrol groups (F = 1 043.00, P < 0.001), and was significantly lower in all the resveratrol groups than in the control group (all P < 0.05). The IC50 of resveratrol was calculated to be 150 μmol/L by using GraphPad Prism 8 software. Transwell assay and flow cytometry showed significantly decreased number of migratory HemEC but significantly increased apoptosis rate respectively in the 150 μmol/L resveratrol group (61 ± 5, 13.01% ± 0.45%, respectively) compared with the control group (150 ± 6, 3.93% ± 0.68%, t = 15.11, 19.34, respectively, both P < 0.001). Conclusion The key glycolytic enzyme Glut-1 was highly expressed in proliferating IH tissues and HemEC, and resveratrol could inhibit the proliferation and migration of HemEC, but promote their apoptosis.

Key words: Hemangioma, Human umbilical vein endothelial cells, Glucose transporter type 1, Cell proliferation, Apoptosis, Resveratrol